National Cancer Institute NCI Cancer Bulletin: A Trusted Source for Cancer Research News
May 3, 2011 • Volume 8 / Number 9


FDA Approves Abiraterone for Advanced Prostate Cancer

A ball-and-stick model of the abiraterone molecule For the second time in a year, the Food and Drug Administration (FDA) has approved a new treatment for men with advanced prostate cancer who, until recently, have had few effective treatment options.

Last Thursday, the agency approved abiraterone (Zytiga) for the treatment of men with metastatic castration-resistant prostate cancer (meaning the disease progresses despite low levels of tumor-fueling hormones) who are no longer responding to the chemotherapy drug docetaxel. Read more > >


A Conversation with Drs. Maureen Hatch and Kiyohiko Mabuchi on the 25th Anniversary of the Chernobyl Nuclear Disaster

The researchers from NCI's Radiation Epidemiology Branch discuss lessons learned from the Chernobyl accident and research on the health consequences of the accident. Read more > >


NCI's Fiscal Picture and Grant Support for FY2011

Last week, NCI Director Dr. Harold Varmus e-mailed staff regarding NCI's budget and the challenges ahead for the cancer research community. View the full text of the email  online.




  • Legislative Update

    • State Cancer Legislative Database Update Now Available
  • Notes

    • NCI's Gottesman and Fraumeni Receive Prestigious Honors
    • NCI Experts Advise U.S. Embassy Staff in Japan during Fukushima Nuclear Crisis
    • NCI's Clinical Assay Development Program Seeks Project Applications
    • President's Cancer Panel Report Focuses on Need for Better Understanding of Diverse Populations
    • Second Telephone Workshop for Cancer Survivors Addresses Weight Changes
    • Registry of Measures for Childhood Obesity Research Available

Selected articles from past issues of the NCI Cancer Bulletin are available in Spanish.

The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.

For more information about cancer, call 1-800-4-CANCER or visit

NCI Cancer Bulletin staff can be reached at

Next Section >